Search
Repligen Corp
RGENAdd to Watchlist
141.010USD
-2.590-1.80%
Close 07-31 16:00（ET）Quotes delayed by 15 min
7.96BMarket Cap
154.37P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Repligen Corp is 8.09, ranking 68 out of 199 in the Healthcare Equipment & Supplies industry. The average price target is 190.00, with a high of 220.00 and a low of 160.00.
Analyst Rating
Based on
22
analysts
Buy
Current Rating
187.053
Target Price
+32.45%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
109
Total
7
Median
9
Average
Company name
Ratings
Analysts
Repligen Corp
RGEN
22
Dexcom Inc
DXCM
32
Stryker Corp
SYK
32
Medtronic PLC
MDT
31
Zimmer Biomet Holdings Inc
ZBH
31
Abbott Laboratories
ABT
29
1
2
3
...
22
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Repligen Corp's expected revenue for the next quarter?
Repligen Corp's expected revenue is 206.67M.
What is Repligen Corp's price target?
Analysts forecast that Repligen Corp's price target is USD 190.00, with the highest forecast at USD 220.00 and the lowest forecast at USD 160.00.
How have Repligen CorpRGEN's recent earnings per share performed?
The market expectation was USD 0.09, while Repligen CorpRGEN's earnings per share (EPS) for the previous quarter was USD 0.15. EPS for the next quarter is expected at USD 0.46.
What is the analyst rating for Repligen Corp?
Based on the ratings of Repligen Corp's stock from 22 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.